がん第 I 相試験における 2 剤併用療法の用量探索法:最近の展開  [in Japanese] Overview of Model-Based Dose-Finding Methods for Combinations of Two Agents in Phase I Oncology Trials  [in Japanese]

Access this Article

Search this Article

Author(s)

    • 平川 晃弘 Hirakawa Akihiro
    • 名古屋大学医学部附属病院先端医療・臨床研究支援センター Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine
    • 松井 茂之 Matsui Shigeyuki
    • 名古屋大学大学院医学系研究科臨床医薬学講座生物統計学分野 Department of Biostatistics, Nagoya University Graduate School of Medicine

Abstract

We discuss toxicity-based dose-finding methods for two-agent combinations in phase I oncology trials. We focus on the four dose-finding methods recently developed, the methods based on 1) a copula-type model, 2) a hierarchical Bayesian model, 3) continual reassessment method with partial ordering (POCRM), and 4) a shrinkage logistic model. We summarize the characteristic of each method and compare the performance among them through simulation studies. In the simulation studies, we examined recommendation rates (RDs) for both true maximum tolerated dose combinations (MTDCs) and unacceptable toxicity dose combinations (UTDCs) under 12 scenarios with 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. Simulation studies demonstrated that the POCRM and method using the shrinkage logistic model outperformed the other two methods in terms of recommending true MTDCs. The RDs for the UTDCs in the method using the shrinkage logistic model were lower than the other three methods.

Journal

  • Japanese Journal of Biometrics

    Japanese Journal of Biometrics 34(2), 81-97, 2014

    The Biometric Society of Japan

Codes

  • NII Article ID (NAID)
    130004721700
  • NII NACSIS-CAT ID (NCID)
    AA11591618
  • Text Lang
    JPN
  • ISSN
    0918-4430
  • NDL Article ID
    025352853
  • NDL Call No.
    Z74-B725
  • Data Source
    NDL  J-STAGE 
Page Top